Gallacher Capital Management LLC Has $104,000 Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA)

Gallacher Capital Management LLC reduced its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) by 59.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,660 shares of the company's stock after selling 103,086 shares during the period. Gallacher Capital Management LLC owned 0.14% of Cassava Sciences worth $104,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Deutsche Bank AG increased its stake in shares of Cassava Sciences by 42.7% in the fourth quarter. Deutsche Bank AG now owns 36,571 shares of the company's stock worth $86,000 after purchasing an additional 10,940 shares during the period. Raymond James Financial Inc. bought a new position in shares of Cassava Sciences in the fourth quarter worth about $147,000. Two Sigma Investments LP increased its stake in shares of Cassava Sciences by 679.1% in the fourth quarter. Two Sigma Investments LP now owns 562,082 shares of the company's stock worth $1,327,000 after purchasing an additional 489,936 shares during the period. Marshall Wace LLP bought a new position in shares of Cassava Sciences in the fourth quarter worth about $50,000. Finally, Two Sigma Advisers LP bought a new position in shares of Cassava Sciences in the fourth quarter worth about $1,432,000. 38.05% of the stock is currently owned by institutional investors.

Cassava Sciences Stock Performance

Shares of Cassava Sciences stock traded down $0.17 during trading on Friday, reaching $2.36. The company's stock had a trading volume of 632,633 shares, compared to its average volume of 1,508,175. The business's fifty day moving average price is $2.10 and its 200-day moving average price is $2.13. The firm has a market cap of $113.77 million, a price-to-earnings ratio of -1.57 and a beta of -2.04. Cassava Sciences, Inc. has a one year low of $1.15 and a one year high of $42.20.

Cassava Sciences (NASDAQ:SAVA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. Sell-side analysts anticipate that Cassava Sciences, Inc. will post -3.97 EPS for the current year.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.